Drugs / LPM3480226
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03844438 | Dec 2018 → Oct 2020 | cancer | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPM3480226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03844438 ↗ |
| Route | Oral | “LPM3480226 tablet will be orally administered” NCT03844438 ↗ |